<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748057</url>
  </required_header>
  <id_info>
    <org_study_id>0653H-833</org_study_id>
    <secondary_id>163314</secondary_id>
    <nct_id>NCT02748057</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833)</brief_title>
  <official_title>A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin Monotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess the safety and tolerability of MK-0653H (Ezetimibe 10 mg+ Rosuvastatin
      2.5 mg) and MK-0653H (Ezetimibe 10 mg+ Rosuvastatin 5.0 mg) through up to 52 weeks in
      Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10
      mg or Rosuvastatin up to 5 mg.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2016</start_date>
  <completion_date type="Actual">December 11, 2017</completion_date>
  <primary_completion_date type="Actual">December 11, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Experience at Least 1 Adverse Event</measure>
    <time_frame>up to 54 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who are Discontinued from the Study Due to Adverse Event</measure>
    <time_frame>up to 52 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">135</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg + Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Ezetimibe 10 mg tablet and 1 Rosuvastatin 2.5 mg capsule/tablet orally, once daily for 52 weeks. If participant does not achieve LDL-C goal after Week 12, dosage of Rosuvastatin may be increased to 5.0 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ezetimibe 10 mg + Rosuvastatin 5.0 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 Ezetimibe 10 mg tablet and 2 Rosuvastatin 2.5 mg capsules/tablets orally, once daily for 52 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe</intervention_name>
    <arm_group_label>Ezetimibe 10 mg + Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Rosuvastatin 5.0 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <arm_group_label>Ezetimibe 10 mg + Rosuvastatin 2.5 mg</arm_group_label>
    <arm_group_label>Ezetimibe 10 mg + Rosuvastatin 5.0 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Japanese

          -  Outpatient with hypercholesterolemia

          -  Female participant who is of reproductive potential has to agree to remain abstinent
             or use (or partner use) two acceptable methods of birth control from date of signed
             informed consent to the 14 days after the last dose of study drug

          -  Will maintain a stable diet that is consistent with the Japan Atherosclerosis Society
             Guideline 2012 (JAS 2012) for prevention of atherosclerotic cardiovascular diseases
             for the duration of the study

        Exclusion Criteria:

          -  Uncontrolled hypertension (treated or untreated)

          -  Uncontrolled type 1 or type 2 diabetes mellitus

          -  Homozygous Familial Hypercholesterolemia or has undergone low-density lipoprotein
             (LDL) apheresis

          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or
             lipoproteins

          -  Has had a gastrointestinal tract bypass, or other significant intestinal malabsorption

          -  History of cancer within the past 5 years (except for successfully treated
             dermatological basal cell or squamous cell carcinoma or in situ cervical cancer)

          -  Human Immunodeficiency Virus (HIV) positive

          -  History of drug/ alcohol abuse within the past 5 years or psychiatric illness not
             adequately controlled and stable on pharmacotherapy

          -  Consumes more than 25 g of alcohol per day

          -  Currently following an excessive weight reduction diet

          -  Currently engages in a vigorous exercise regimen (e.g.; marathon training, body
             building training etc.) or intends to start training during the study

          -  Hypersensitivity or intolerance to Ezetimibe or Rosuvastatin

          -  Myopathy or rhabdomyolysis with Ezetimibe or any statin

          -  Pregnant or lactating

          -  Taking any other investigational drugs and/or has taken any investigational drugs
             within 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2016</study_first_submitted>
  <study_first_submitted_qc>April 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

